143 related articles for article (PubMed ID: 1651306)
1. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
Phillips TL; Levin VA; Ahn DK; Gutin PH; Davis RL; Wilson CB; Prados MD; Wara WM; Flam MS
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):709-14. PubMed ID: 1651306
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Groves MD; Maor MH; Meyers C; Kyritsis AP; Jaeckle KA; Yung WK; Sawaya RE; Hess K; Bruner JM; Peterson P; Levin VA
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):127-35. PubMed ID: 10477016
[TBL] [Abstract][Full Text] [Related]
3. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Levin VA; Maor MH; Thall PF; Yung WK; Bruner J; Sawaya R; Kyritsis AP; Leeds N; Woo S; Rodriguez L
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):357-64. PubMed ID: 7673023
[TBL] [Abstract][Full Text] [Related]
5. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
[TBL] [Abstract][Full Text] [Related]
6. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
Prados MD; Scott C; Sandler H; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1109-15. PubMed ID: 10613302
[TBL] [Abstract][Full Text] [Related]
7. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
9. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
Jeremic B; Jovanovic D; Djuric LJ; Jevremovic S; Mijatovic LJ
J Chemother; 1992 Apr; 4(2):123-6. PubMed ID: 1321239
[TBL] [Abstract][Full Text] [Related]
10. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.
Gutin PH; Prados MD; Phillips TL; Wara WM; Larson DA; Leibel SA; Sneed PK; Levin VA; Weaver KA; Silver P
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):601-6. PubMed ID: 1651302
[TBL] [Abstract][Full Text] [Related]
11. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD
Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250
[TBL] [Abstract][Full Text] [Related]
13. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Levin VA; Silver P; Hannigan J; Wara WM; Gutin PH; Davis RL; Wilson CB
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):321-4. PubMed ID: 2154418
[TBL] [Abstract][Full Text] [Related]
14. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
15. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.
Hegarty TJ; Thornton AF; Diaz RF; Chandler WF; Ensminger WD; Junck L; Page MA; Gebarski SS; Hood TW; Stetson PL
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):421-8. PubMed ID: 2168357
[TBL] [Abstract][Full Text] [Related]
16. BUdR radiosensitization in anaplastic astrocytoma.
Yung WK
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1105-6. PubMed ID: 10613300
[No Abstract] [Full Text] [Related]
17. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
Levin VA; Yung WK; Bruner J; Kyritsis A; Leeds N; Gleason MJ; Hess KR; Meyers CA; Ictech SA; Chang E; Maor MH
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):58-66. PubMed ID: 12007942
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
19. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Levin VA; Wara WM; Davis RL; Vestnys P; Resser KJ; Yatsko K; Nutik S; Gutin PH; Wilson CB
J Neurosurg; 1985 Aug; 63(2):218-23. PubMed ID: 2991486
[TBL] [Abstract][Full Text] [Related]
20. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
J Neurooncol; 1994; 21(2):177-85. PubMed ID: 7861194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
